Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.89 USD | -1.37% | +2.16% | 0.00% |
Apr. 30 | Morgan Stanley Starts Contineum Therapeutics With Overweight Rating | MT |
Apr. 30 | Stifel Starts Contineum Therapeutics With Buy Rating, $29 Price Target | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 15M | Capitalization | 405M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | 204M | Net cash position 2025 * | 59.74M | EV / Sales 2025 * | 23 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 31 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 65.58% |
1 day | -1.37% | ||
1 week | +2.16% | ||
Current month | +1.51% | ||
1 month | -0.60% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 15.82 | -1.80% | 5 384 |
24-05-23 | 16.11 | +1.58% | 118,222 |
24-05-22 | 15.86 | -0.88% | 25,253 |
24-05-21 | 16 | +1.85% | 25,345 |
24-05-20 | 15.71 | +1.35% | 50,676 |
Delayed Quote Nasdaq, May 24, 2024 at 10:33 am EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
0.00% | 405M | |
+65.95% | 62.86B | |
-1.02% | 41.38B | |
+45.66% | 40.38B | |
-8.93% | 27.64B | |
+13.54% | 26.46B | |
-22.94% | 18.9B | |
+4.39% | 12.67B | |
+23.47% | 12.27B | |
+27.65% | 12.07B |
- Stock Market
- Equities
- CTNM Stock